指南与共识中枢神经肿瘤放疗

ESTRO-EANO指南:IDH突变型WHO中枢神经系统2级和3级弥漫性胶质瘤的靶区勾画与放射治疗

ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma.
指南 / 共识 · Radiother Oncol · 2024-10-24

该指南由ESTRO指南委员会中枢神经亚组组织15名欧洲专家,采用改良两步Delphi法制定,讨论IDH突变型2级和3级弥漫性胶质瘤的影像、靶区勾画、剂量分割与技术。结论推荐GTV包括术后残留肿瘤和切除腔,2级肿瘤GTV包括T2/FLAIR异常并外扩10 mm,3级肿瘤包括T2/FLAIR异常(除外水肿区)并外扩15 mm;2级推荐50.4 Gy/28次,3级推荐59.4 Gy/33次,首选IMRT技术。

要点

  • GTV应包括术后残留肿瘤体积和切除腔,T1增强提示残留肿瘤时应纳入。
  • 2级肿瘤GTV包括T2/FLAIR异常,外扩10 mm;3级肿瘤包括T2/FLAIR异常但除外水肿区,外扩15 mm。
  • 2级推荐50.4 Gy/28次,3级推荐59.4 Gy/33次,首选IMRT技术。

核心结论

  • GTV应包括术后残留肿瘤体积和切除腔,T1增强提示残留肿瘤时应纳入;2级肿瘤GTV包括T2/FLAIR异常,3级肿瘤GTV包括T2/FLAIR异常但除外水肿区。
  • 2级肿瘤推荐GTV至CTV外扩10 mm,3级肿瘤推荐15 mm;2级推荐50.4 Gy/28次,3级推荐59.4 Gy/33次;首选IMRT技术。

研究设计与样本

  • ESTRO指南委员会中枢神经亚组提名15名欧洲专家,确定本指南问题,成立四个工作组分别讨论影像、靶区勾画、放疗技术和分割。
  • 进行文献检索并讨论现有文献,采用改良两步Delphi法,以多数投票形成决策或标出不确定领域。

主要发现

  • 关键问题包括确定靶区定义所需的影像、靶区勾画与边缘大小,以及包括质子治疗等不同计划技术在内的技术方面。

关键数值与推荐

  • GTV应包括术后残留肿瘤体积和切除腔;T1增强提示残留肿瘤时应纳入GTV。
  • 2级肿瘤GTV包括T2/FLAIR异常;3级肿瘤GTV包括T2/FLAIR异常,但除外水肿区。
  • 2级肿瘤推荐GTV至CTV外扩10 mm,3级肿瘤推荐15 mm;2级推荐50.4 Gy/28次,3级推荐59.4 Gy/33次;首选IMRT技术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline will discuss radiotherapeutic management of IDH-mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities, tumour volume delineation, irradiation dose and fractionation. METHODS: The ESTRO Guidelines Committee, CNS subgroup, nominated 15 European experts who identified questions for this guideline. Four working groups were established addressing specific questions concerning imaging, target volume delineation, radiation techniques and fractionation. A literature search was performed, and available literature was discussed. A modified two-step Delphi process was used with majority voting resulted in a decision or highlighting areas of uncertainty. RESULTS: Key issues identified and discussed included imaging needed to define target definition, target delineation and the size of margins, and technical aspects of treatment including different planning techniques such as proton therapy. CONCLUSIONS: The GTV should include any residual tumour volume after surgery, as well as the resection cavity. Enhancing lesions on T1 imaging should be included if they are indicative of residual tumour. In grade 2 tumours, T2/FLAIR abnormalities should be included in the GTV. In grade 3 tumours, T2/FLAIR abnormalities should also be included, except areas that are considered to be oedema which should be omitted from the GTV. A GTV to CTV expansion of 10 mm is recommended in grade 2 tumours and 15 mm in grade 3 tumours. A treatment dose of 50.4 Gy in 28 fractions is recommended in grade 2 tumours and 59.4 Gy in 33 fractions in grade 3 tumours. Radiation techniques with IMRT are the preferred approach.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Baumert BG, P M Jaspers J, Keil VC, et al. ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma. Radiother Oncol. 2024. PMID: 39454886. doi:10.1016/j.radonc.2024.110594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。